Glassia - Chronic Augmentation Therapy For Alpha1-proteinase Inhibitor Deficiency | Enhance Emphysema Management And Maintenance

Our rich domain expertise has assisted us in grabbing a place of prominence in the industry as one of the eminent manufacturer and supplier of Glassia.

Indications:

GLASSIA is indicated for chronic augmentation and maintenance therapy in individuals with emphysema due to congenital deficiency of alpha1-proteinase inhibitor (Alpha1-PI), also known as alpha1-antitrypsin (AAT) deficiency.


The effect of augmentation therapy with GLASSIA or any Alpha1-PI product on pulmonary exacerbations and on the progression of emphysema in Alpha1-PI deficiency has not been demonstrated in randomized, controlled clinical trials. Clinical data demonstrating the long-term effects of chronic augmentation and maintenance therapy of individuals with GLASSIA are not available. GLASSIA is not indicated as therapy for lung disease in patients in whom severe Alpha1-PI deficiency has not been established.